Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D and COVID-19 Trial (VIVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04536298
Recruitment Status : Recruiting
First Posted : September 2, 2020
Last Update Posted : June 14, 2021
Sponsor:
Collaborators:
Harvard Medical School
Harvard School of Public Health
Fenway Health and Beth Israel Deaconess Medical Center
Tishcon Corporation
Takeda
Quest Diagnostics-Nichols Insitute
Karolinska Institutet
Philanthropic donations
Information provided by (Responsible Party):
JoAnn E. Manson, MD, Brigham and Women's Hospital

Brief Summary:
The Vitamin D and COVID-19 Trial (VIVID) is a nationwide randomized clinical trial in 2700 U.S. men and women to investigate whether taking a daily dietary supplement of vitamin D for 4 weeks reduces disease severity in participants newly diagnosed with COVID-19, and reduces the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in household contacts of someone newly diagnosed with COVID-19 (as documented by seroconversion).

Condition or disease Intervention/treatment Phase
COVID-19 Dietary Supplement: vitamin D Dietary Supplement: Placebo Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2700 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members
Actual Study Start Date : December 28, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D

Arm Intervention/treatment
Active Comparator: Vitamin D
Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
Dietary Supplement: vitamin D
Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
Other Names:
  • vitamin D3
  • cholecalciferol

Placebo Comparator: Placebo
Placebo
Dietary Supplement: Placebo
Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28




Primary Outcome Measures :
  1. Rate of seeking healthcare visits (including hospitalizations, emergency room visits, or ambulatory or virtual clinician visits) for symptoms or concerns related to COVID-19 or deaths in participants newly diagnosed with COVID-19 (index cases) [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Rate of hospitalization/death or emergency room visits related to COVID-19 infection among index cases [ Time Frame: 4 weeks ]
  2. Rate of hospitalization/death or emergency room visits related to COVID-19 in index cases with high risk for disease progression (defined as age 50 or older, or age 18-49 with at least one co-morbidity or risk factor) [ Time Frame: 4 weeks ]
  3. Self-reported disease severity in index cases [ Time Frame: 4 weeks ]
    Severity: 1=no COVID-19 illness; 2=COVID-19 illness with no hospitalization; 3=COVID-19 illness with hospitalization; or 4=death

  4. Time to seeking healthcare (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) or death in index cases [ Time Frame: 4 weeks ]
  5. ICU admission/ventilation support in index cases [ Time Frame: 4 weeks ]
  6. SARS-CoV-2 infection in close household contacts [ Time Frame: 4 weeks ]
    Seroconversion or other positive test

  7. Time to symptom onset and self-reported disease severity in household contacts [ Time Frame: 4 weeks ]
    Severity: 1=no COVID-19 illness; 2=COVID-19 illness with no hospitalization; 3=COVID-19 illness with hospitalization; or 4=death

  8. Rate of healthcare visits (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) for symptoms or concerns related to COVID-19 infection or deaths among household contacts who contract COVID-19 [ Time Frame: 4 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion/exclusion criteria for INDEX CASES:

Inclusion criteria

  1. Adults aged 18 years or older who are newly diagnosed with COVID-19 infection within 7 days of testing.
  2. Ability and willingness to understand and provide informed consent.

Exclusion criteria

  1. Known current pregnancy.
  2. Current hospitalization.
  3. Unable to complete online questionnaires or adhere to study requirements.
  4. Consume more than 1000 IU per day of vitamin D from all supplemental sources combined (individual vitamin D supplements, calcium plus vitamin D supplements, medications with vitamin D [e.g., Fosamax Plus D], and multivitamins) in the past 4 weeks.
  5. Use of prescription vitamin D treatments (Calcitriol [Rocaltrol, Calcitrol, Vectical, Calcijex] or Paricalcitol [Zemplar]).
  6. Consume supplements with more than 1200 mg calcium per day.
  7. Known diagnosis of hypercalcemia or a condition associated with vitamin D hypersensitivity.
  8. Prior diagnosis of cancer *AND* currently undergoing radiation, chemotherapy, or immunotherapy.
  9. Kidney failure or dialysis; severe liver disease or cirrhosis.
  10. Any parathyroid conditions.
  11. Use of medications for seizures or epilepsy. Examples: Carbamazepine (Carbatrol, Tegretol), Phenytoin (Dilantin, Phenytek), Valproic acid (Depakene), Oxcarbazepine (Oxtellar, Trileptal), Phenobarbital, Topiramate (Topamax).
  12. Use of digoxin.
  13. Inability to receive an overnight express mail shipment of study pills at a home address.
  14. Participation in other COVID-19 trials.

Inclusion/exclusion criteria for HOUSEHOLD CONTACTS:

Inclusion criteria:

  1. Persons aged 18 years or older who live in the same household with an index individual and have been identified as the closest household contact within the same household (limited to 1 per household).
  2. Persons aged 18 years or older who live in household with someone who tested positive for COVID-19 within past 7 days but not participating in VIVID.
  3. Ability and willingness to understand and provide informed consent.

Exclusion criteria:

  1. Known current pregnancy.
  2. History of SARS-CoV-2 infection.
  3. Receipt of a SARS-CoV-2 vaccination or monoclonal antibody.
  4. Unable to complete online questionnaires or adhere to study requirements.
  5. Consume more than 1000 IU per day of vitamin D from all supplemental sources combined (individual vitamin D supplements, calcium plus vitamin D supplements, medications with vitamin D [e.g., Fosamax Plus D], and multivitamins) in the past 4 weeks.
  6. Use of prescription vitamin D treatments (Calcitriol [Rocaltrol, Calcitrol, Vectical, Calcijex] or Paricalcitol [Zemplar]).
  7. Consume supplements with more than 1200 mg calcium per day.
  8. Known diagnosis of hypercalcemia or a condition associated with vitamin D hypersensitivity.
  9. Prior diagnosis of cancer *AND* currently undergoing radiation, chemotherapy, or immunotherapy.
  10. Kidney failure or dialysis; severe liver disease or cirrhosis.
  11. Any parathyroid condition.
  12. Use of medications for seizures or epilepsy. Examples: Carbamazepine (Carbatrol, Tegretol), Phenytoin (Dilantin, Phenytek), Valproic acid (Depakene), Oxcarbazepine (Oxtellar, Trileptal), Phenobarbital, Topiramate (Topamax).
  13. Use of digoxin.
  14. Inability to receive an overnight express mail shipment of study pills at a home address.
  15. Participation in other COVID-19 trials.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04536298


Contacts
Layout table for location contacts
Contact: Trisha Copeland, MS, RD 1-877-517-2555 pcopeland2@bwh.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02215
Contact: Trisha Copeland, MS, RD    877-517-2555    pcopeland2@bwh.harvard.edu   
Sponsors and Collaborators
Brigham and Women's Hospital
Harvard Medical School
Harvard School of Public Health
Fenway Health and Beth Israel Deaconess Medical Center
Tishcon Corporation
Takeda
Quest Diagnostics-Nichols Insitute
Karolinska Institutet
Philanthropic donations
Investigators
Layout table for investigator information
Principal Investigator: JoAnn E Manson, MD, DrPH Brigham and Women's Hospital
Principal Investigator: Rui Wang, PhD Harvard Medical School
Principal Investigator: Davaasambuu Ganmaa, PhD Harvard School of Public Health
Publications:
Layout table for additonal information
Responsible Party: JoAnn E. Manson, MD, Professor of Medicine, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT04536298    
Other Study ID Numbers: 2020P002815
First Posted: September 2, 2020    Key Record Dates
Last Update Posted: June 14, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Details will be provided at a later date.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by JoAnn E. Manson, MD, Brigham and Women's Hospital:
COVID-19
SARS-CoV-2 infection
coronavirus
vitamin D
hospitalization
death
disease severity
treatment
prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Vitamin D
Ergocalciferols
Cholecalciferol
Vitamins
Micronutrients
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents